WuXi Biologics

Graphic of two hands shaking under a red and purple light

Candid adds another T-cell engager via $925M WuXi Biologics deal

Candid continues to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi for a preclinical candidate.

James Waldron Jan 7, 2025 8:42am

BioNTech pays WuXi $20M for 2 preclinical monoclonal antibodies

Jan 11, 2024 9:23am

deal handshake business cooperation partnerships

WuXi CRDMO spinoff WuXi XDC partners with IntoCell

Jan 3, 2024 11:05am

photo of a number of hands in the center

Mediar gets a spark from Pfizer's Ignite program

Oct 25, 2023 10:50am

GSK pays WuXi $40M for preclinical anti-cancer bispecific

Jan 5, 2023 5:45am

CANbridge posts early-phase data on rival to AstraZeneca drug

Feb 7, 2022 8:35am